Mark Ross, MD
Neurology · Denver, CONPI 1164405080
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,535 of the $4,867 with a category attached, or 72.6%. Tanabe Pharma America, Inc. accounts for 95.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $4,821 and has fallen 99.5% since, to $24 in 2023.
Across 13 payments — averaging $374.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tanabe Pharma America, Inc.$5K
- Shire North American Group Inc$120
- AstraZeneca$33
- Boston Scientific$24
- AbbVie$21
Across 1 payment — averaging $6250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Enterprises LLC$6K
What the payments were for
- Consulting fees$3,53573%
- Travel & lodging$81217%
- Food & beverage$52011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tanabe Pharma America, Inc. | 9 | $4,668 |
| Shire North American Group Inc | 1 | $120 |
| AstraZeneca | 1 | $33 |
| Boston Scientific | 1 | $24 |
| AbbVie | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Radicava$4,535
- GAMMAGARD LIQUID$120
How this compares
$4,867 in reported general payments places this provider in the 65th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Denver
- Justin MoonDenver$1.4M
- Michael AmentDenver$457K
- Adam WolffDenver$364K
- Shankar PerumalDenver$61K
- Jinny TaveeDenver$58K
- Alexander FeldmanDenver$28K
- James McNuttDenver$27K
- Jared YarnellDenver$27K
- Ralph RoundDenver$26K
- Jonathan DatarDenver$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.